摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbohydrazide | 22721-31-9

中文名称
——
中文别名
——
英文名称
2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbohydrazide
英文别名
——
2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbohydrazide化学式
CAS
22721-31-9
化学式
C10H15N3OS
mdl
——
分子量
225.315
InChiKey
PPNSKPIAWDTFMX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.1
  • 重原子数:
    15
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    109
  • 氢给体数:
    3
  • 氢受体数:
    4

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbohydrazide溶剂黄146 、 sodium nitrite 作用下, 以 为溶剂, 反应 0.5h, 以66%的产率得到2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbonylazide
    参考文献:
    名称:
    一系列新的环戊(hepta)[ b ]噻吩和稠合环庚[ b ]噻吩类似物的合成,抗菌,抗群体感应,抗肿瘤和细胞毒活性
    摘要:
    合成了新系列的环戊(庚)[ b ]噻吩和稠合的环庚[ b ]噻吩类似物。评估了新的类似物对大肠杆菌ATCC 12435,蜡状芽孢杆菌UW 85和金黄色葡萄球菌的抗菌效果。与氨苄青霉素相比,化合物5a,6b和12对所有选定的细菌菌株均具有显着活性。还检查了相同类似物对白色念珠菌和烟曲霉293的抗真菌功效,而5a,b和12对两种被测真菌均显示出优异的功效。而且,图4b,6a,14a和17证明了对A的有趣的抗真菌功效。曲霉。评估了相同的类似物对紫细菌ATCC 12472的抗群体感应功效,而5a,12和15a表现出中等活性。新的类似物还因其对HepG2,MCF-7和HT-29癌细胞系的体外抗肿瘤活性而备受推崇。结果表明6b和10是针对三种测试细胞系的最有效的类似物。此外,5a,6a,7和15a对所有测试的细胞系显示出有趣的活动。针对在小鼠中对EAC的体内抗肿瘤活性以及对W138人正常细胞系的体外细
    DOI:
    10.1016/j.ejmech.2017.08.066
  • 作为产物:
    描述:
    2-氨基环庚烷并[B]噻吩-3-羧酸乙酯4-二甲氨基吡啶 、 (benzotriazo-1-yloxy)tris(dimethylamino)phosphonium hexafluorophosphate 、 三氟乙酸 、 sodium hydroxide 、 作用下, 以 1,4-二氧六环乙醇二氯甲烷N,N-二甲基甲酰胺 为溶剂, 反应 8.5h, 生成 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carbohydrazide
    参考文献:
    名称:
    作为A 1腺苷受体变构调节剂的2-氨基-4,5,6,7,8,9-六氢环辛基[ b ]噻吩的合成及生物学评价
    摘要:
    制备了一系列2-氨基-4,5,6,7,8,9-六氢环辛基[ b ]噻吩,并将其评估为A 1腺苷受体(AR)的潜在变构调节剂。探索了3位的结构-活性关系,以及改变了环烷基环的大小。在A 1 -AR介导的ERK1 / 2磷酸化测定中,在3位具有酰胺和酰肼基的2-氨基噻吩是完全无活性的,但是大多数3-苯甲酰基取代的化合物对正构激动剂介导的反应表现出变构作用,[R-PIA。尽管通过从3-苯甲酰基系列中的环戊基环变为环己基环而发现激动和变构活性都增加,但是当进一步增加环的大小时,观察到了减少。3-苯甲酰基基团的苯环上的取代基的变化也影响了这些化合物的活性。
    DOI:
    10.1016/j.bmcl.2011.04.080
点击查看最新优质反应信息

文献信息

  • [EN] COMPOUND FOR INHIBITING THE GROWTH AND PROLIFERATION OF HUMAN LIVER CANCER CELLS AND METHOD FOR SYNTHESIZING IT<br/>[FR] COMPOSÉ POUR INHIBER LA CROISSANCE ET LA PROLIFÉRATION DE CELLULES DE CANCER DU FOIE HUMAIN ET SON PROCÉDÉ DE SYNTHÈSE
    申请人:ALGHAMDI ZAINAB SAEED
    公开号:WO2018056872A1
    公开(公告)日:2018-03-29
    The compound 2-((4-nitrophenyl)amino)-6,7,8,9-tetrahydro-3H-cyclohepta[4,5]thieno[2, 3-d]pyrimidin-4(5H)-one and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation of human liver cancer cells HepG2. The compound has an inhibitory concentration value (IC50) of 0.7 μg, compared to reference medication Doxorubicin that has an (IC50) value of 1.2 μg. It further surpasses that reference medication Doxorubicin at all tested concentraions. The method includes the steps of: preparing a first compound of cycloheptanone, ethyl cyanoacetate, sulfur, ethanol and diethyl amine; preparing a second compound by heating of the first compound with excess of hydrazine hydrate in absolute ethanol as solvent; and preparing the effective compound of the invention by reaction of the second chemical compound with 4-nitrophenylisothiocyanate in dry dimethylformamide as solvent.
    该化合物为2-((4-硝基苯基)氨基)-6,7,8,9-四氢-3H-环庚并[4,5]噻吩[2,3-d]嘧啶-4(5H)-酮,以及合成它的方法,其中该化合物有效抑制人类肝癌细胞HepG2的生长和增殖。该化合物的抑制浓度值(IC50)为0.7微克,而参考药物多柔比星的IC50值为1.2微克。在所有测试浓度下,它进一步超越了多柔比星参考药物。该方法包括以下步骤:准备环庚酮、乙基氰乙酸酯、硫、乙醇和二乙胺的第一化合物;通过在绝对乙醇中过量加热第一化合物与肼水合物制备第二化合合物;并通过在干二甲基甲酰胺作为溶剂的条件下将第二化合物与4-硝基苯基异硫氰酸酯反应制备出发明中的有效化合物。
  • [EN] A CHEMICAL COMPOUND FOR INHIBITING THE GROWTH AND PROLIFERATION OF HUMAN LIVER CANCER CELLS HEPG2 AND METHOD FOR SYNTHESIZING IT<br/>[FR] COMPOSÉ CHIMIQUE POUR INHIBER LA CROISSANCE ET LA PROLIFÉRATION DE CELLULES DE CANCER DU FOIE HUMAIN HEPG2 ET SON PROCÉDÉ DE SYNTHÈSE
    申请人:ALGHAMDI ZAINAB SAEED
    公开号:WO2018007843A1
    公开(公告)日:2018-01-11
    The compound 2-((4-Nitrophenyl)amino)-7,8,9,10-tetrahydrocyclohepta[4,5]thieno[2,3-d][1,3,4]thiadiazolo[3,2-a]pyrimidin-11(6H)-one and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation of human liver cancer cells HepG2. The compound has a higher efficiency to inhibit the growth and proliferation of these cells as it has an inhabitation concentration value (IC50) of 0.7 μg, compared to reference medication Doxorubicin that has an (IC50) value of 1.2 μg. It further surpasses that reference medication at all tested concentrations. The method includes the steps of: preparing a first compound of cycloheptanone, ethylcyanoacetate, sulfur, ethanol and diethylamine; preparing a second compound by heating of the first compound with hydrazine hydrate in absolute ethanol as solvent; preparing a third compound by heating the second compound with carbon disulphide in pyridine; and preparing the compound of the invention by reacting the third compound with 4-nitrophenylisothiocyanate in dimethylformamide as solvent.
    这种化合物是2-((4-硝基苯基)氨基)-7,8,9,10-四氢环庚并[4,5]噻吩[2,3-d][1,3,4]噻二唑并[3,2-a]嘧啶-11(6H)-酮,以及合成它的方法,其中该化合物有效抑制人类肝癌细胞HepG2的生长和增殖。该化合物在抑制这些细胞的生长和增殖方面效率更高,其抑制浓度值(IC50)为0.7μg,而参考药物多柔比星的IC50值为1.2μg。它在所有测试浓度下均超过了参考药物。该方法包括以下步骤:制备环庚酮、氰乙酸乙酯、硫、乙醇和二乙胺的第一化合物;通过在绝对乙醇中与水合肼加热第一化合物制备第二化合物;通过在吡啶中与二硫化碳加热第二化合物制备第三化合物;通过在二甲基甲酰胺中与4-硝基苯基异硫氰酸酯反应制备发明的化合物。
  • COMPOUND FOR INHIBITING THE GROWTH AND PROLIFERATION OF HUMAN LIVER CANCER CELLS AND METHOD FOR SYNTHESIZING IT
    申请人:Alghamdi Zainab Saeed
    公开号:US20160280717A1
    公开(公告)日:2016-09-29
    The compound “2-((4-nitrophenyl)amino)-6,7,8,9-tetrahydro-3H-cyclohepta[4,5]thieno-[2,3-d]pyrimidin-4(5H)-one” and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation of human liver cancer cells HepG2. The compound has an inhibitory concentration value (IC 50 ) of 0.7 μg, compared to reference medication Doxorubicin that has an (IC 50 ) value of 1.2 μg. It further surpasses that reference medication Doxorubicin at all tested concentraions. The method includes the steps of: preparing a first compound of cycloheptanone, ethylcyanoacetate, sulfur, ethanol and diethyl amine; preparing a second compound by heating of the first compound with excess of hydrazine hydrate in absolute ethanol as solvent; and preparing the effective compound of the invention by reaction of the second chemical compound with 4-nitrophenylisothiocyanate in dry dimethylformamide as solvent.
    这个化合物“2-((4-硝基苯基)氨基)-6,7,8,9-四氢-3H-环庚并[4,5]噻吩-[2,3-d]嘧啶-4(5H)-酮”及其合成方法,其中该化合物有效抑制人肝癌细胞HepG2的生长和增殖。该化合物的抑制浓度值(IC50)为0.7微克,而参考药物多柔比星的IC50值为1.2微克。在所有测试浓度下,它进一步超越了参考药物多柔比星。该方法包括以下步骤:准备环庚酮、氰乙酸乙酯、硫、乙醇和二乙胺的第一化合物;通过在绝对乙醇中过量加热第一化合物与水合肼的第二化合物;通过在干二甲基甲酰胺中与4-硝基苯基异硫氰酸酯反应制备本发明的有效化合物。
  • COMPOUND FOR THE TREATMENT OF HUMAN LIVER CANCER AND METHOD FOR SYNTHESIZING IT
    申请人:Alghamdi Zainab Saeed
    公开号:US20160200740A1
    公开(公告)日:2016-07-14
    The compound “2-((4-nitrophenyl)amino)-7,8,9,10-tetrahydro cyclohepta[4,5]thieno[2,3-d][1,3,4]thiadiazolo[3,2-a]pyrimidin-11(6H)-one” and method of synthesizing it, wherein the compound is effective to inhibit the growth and proliferation of human liver cancer cells HepG2. The compound has a higher efficiency to inhibit the growth and proliferation of these cells as it has an inhibitory concentration value (IC 50 ) of 0.7 μg, compared to reference medication Doxorubicin that has an (IC 50 ) value of 1.2 μg. It further surpasses that reference medication at all tested concentrations. The method includes the steps of: preparing a first compound of cycloheptanone, ethylcyanoacetate, sulfur, ethanol and diethylamine; preparing a second compound by heating of the first compound with excess of hydrazine hydrate in absolute ethanol as solvent; preparing a third compound by heating the second compound with carbon disulphide in dry pyridine; and preparing the compound of the invention by reacting the third compound with 4-nitrophenylisothiocyanate in dry N,N-methylformamide as solvent.
    这个化合物是“2-((4-硝基苯基)氨基)-7,8,9,10-四氢环庚并[4,5]噻吩[2,3-d][1,3,4]噻二唑并[3,2-a]嘧啶-11(6H)-酮”,以及合成它的方法,其中这个化合物有效地抑制人类肝癌细胞HepG2的生长和增殖。与参考药物多柔比星(Doxorubicin)的IC50值为1.2μg相比,该化合物具有更高的效率来抑制这些细胞的生长和增殖,其IC50值为0.7μg。它在所有测试浓度下进一步超越了参考药物。该方法包括以下步骤:制备环庚酮、乙基氰乙酸酯、硫、乙醇和二乙胺的第一化合物;通过在绝对乙醇中用过量的水合肼加热第一化合物制备第二化合物;通过在干燥吡啶中用二硫化碳加热第二化合物制备第三化合物;通过在干燥N,N-甲基甲酰胺中用4-硝基苯基异硫氰酸酯与第三化合物反应制备该发明的化合物。
  • US9447119B2
    申请人:——
    公开号:US9447119B2
    公开(公告)日:2016-09-20
查看更多

同类化合物

酮替芬EP杂质A 酮替芬 苯噻啶苹果酸盐 苯噻啶盐酸盐 苯噻啶 益托洛替芬 富马酸酮替芬 去甲酮替芬富马酸氢盐 乙基2-[(乙基氨基甲硫杂酰)氨基]-5,6,7,8-四氢-4H-环庚三烯并[b]噻吩-3-羧酸酯 [2,3-d]噻吩并环庚三烯酮 9-氧代酮替芬 9,10-二溴-9,10-二氢-4H-苯并[4,5]环庚并[1,2-b]噻吩-4-酮 9,10-二氧代酮替芬 9, 10-二氢-4H-苯并[4, 5]环庚三烯[1, 2-b]噻吩-4-酮 6H-环庚三烯并[c]噻吩-6-酮,1,3,5,7-四甲基- 5,6,7,8-四氢-4h-环庚基[b]噻吩-2-羧酸 5,6,7,8-四氢-4H-环庚[b]噻吩-2-羧酸酰肼 4-羟基酮替芬 4-(哌啶-4-亚基)-4H-苯并[4,5]环庚三烯并[1,2-B]噻吩-10(9H)-酮 4-(3'-甲基氨基丙基亚基)-9,10-二氢-4H-苯并(4,5)环庚并(1,2-b)噻吩 4,9-二氢-4-(1-甲基-4-哌啶基亚基)-10H-苯并[4,5]环庚三烯并[1,2-b]噻吩-10-酮 N-氧化物; 酮替芬 N-氧化物 2-溴-9,10-二氢-4H-苯并(4,5)环庚并(1,2-b)噻吩-4-酮 2-氯-N-(3-氰基-5,6,7,8-四氢-4H-环戊并[b]噻吩-2-基)-乙酰胺 2-氨基环庚烷并[B]噻吩-3-羧酸乙酯 2-氨基-N-甲基-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-甲酰胺 2-氨基-N-乙基-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-甲酰胺 2-氨基-5,6,7,8-四氢-4H-环庚基[b]噻吩-3-羧酰胺 2-氨基-5,6,7,8-四氢-4H-环庚基[b]噻吩-3-甲腈 2-氨基-5,6,7,8-四氢-4H-环庚[B]噻吩-3-甲酸甲酯 2-[(3-氯-1-氧代丙基)氨基]-5,6,7,8-四氢-4H-环庚并[b]噻吩-3-羧酸乙酯 2-(2-氯乙酰基氨基)-5,6,7,8-四氢-4H-环庚[b]噻吩-3-羧酸乙酯 10-甲氧基-4H-苯并[4,5]环庚三烯并[1,2-b]噻吩-4-酮 10-甲氧基-4-(1-甲基-4-哌啶基)-4H-苯并[4,5]环庚三烯并[1,2-B]噻吩-4-醇 (3E)-3-(9,10-二氢-4H-苯并[4,5]环庚三烯并[1,2-b]噻吩-4-亚基)-N,N-二甲基丙烷-1-胺 10-methoxy-8-nitro-5,6-dihydro-4H-benzo[6,7]cyclohepta[1,2-b]thiophene 1,7,9-trimethyl-1,4,5,6-tetrahydrothieno[3',4':6,7]cyclohepta[1,2-c]pyrazole NGB-4420 4-[(Z)-1-phenylbutylidene]-4,6,7,8-tetrahydrocyclohepta[b]thiophen-5-one N-[3-(cyclobutylcarbonyl)-5,6,7,8-tetrahydro-4H-5,8-epoxycyclohepta[b]thien-2-yl]-N'-(1,1-dimethylpropyl)urea (2-amino-5,6,7,8-tetrahydro-4H-5,8-epoxycyclohepta[b]thien-3-yl)(cyclobutyl)methanone 2-[3-(3-methyl[1,2,4]oxadiazol-5-yl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophen-2-ylcarbamoyl]cyclopent-1-enecarboxylic acid 2,8-dihexylcyclohepta[2,1-b:3,4-b']dithiophene methyl 2-(4-methylphenyl)-7,8-dihydro-6H-[7]annuleno[b]thiophene-5-carboxylate ethyl 2-(3-(naphthalen-1-yl)thioureido)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate 2-amino-N-(2-pyridinyl)-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide 2-amino-N-cyclohexyl-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxamide isopropyl 2-amino-5,6,7,8-tetrahydro-4H-cyclohepta[b]thiophene-3-carboxylate 4-allyl-9,10-dihydro-4H-benzo[4,5]cyclohepta[1,2-b]thiophene PCM-0102200 4-{1-[2-[2-(2-hydroxyethoxy)ethoxy]ethyl]piperidin-4-ylidene}-4H-benzo[4,5]cyclohepta[1,2-b]thiophene-10(9H)one hydrobromide